Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Exarafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre
    Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre

    05 Mar 2024

    // PRESS RELEASE

    https://www.pierre-fabre.com/en/press_release/kinnate-biopharma-inc-sells-its-investigational-pan-raf-inhibitor-exarafenib-to

    PRESS RELEASE
    05 Mar 2024
    Share Share
    Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre
    Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre

    01 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/01/2838802/0/en/Kinnate-Biopharma-Inc-Sells-Its-Investigational-Pan-RAF-Inhibitor-Exarafenib-to-Pierre-Fabre-Laboratories.html

    GLOBENEWSWIRE
    01 Mar 2024
    Share Share
    First Report of +ve Dose Escalation Data Supports Best-in-Class Exarafenib
    First Report of +ve Dose Escalation Data Supports Best-in-Class Exarafenib

    17 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/17/2648391/0/en/First-Report-of-Positive-Dose-Escalation-Data-Supports-Best-in-Class-Profile-for-Investigational-Exarafenib-as-a-Single-Agent-and-in-Combination-with-Binimetinib-in-BRAF-altered-Ca.html

    GLOBENEWSWIRE
    17 Apr 2023
    Share Share